The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib

Internal Medicine

Volumn 51, Issue 19, 2012, Pages 2771-2774

  Iwanaga, Kentaro ^a,b   Sueoka Aragane, Naoko ^a   Nakamura, Tomomi ^a   Mori, Daisuke ^b   Kimura, Shinya ^a  

^a SAGA UNIVERSITY   (Japan)

^b Saga Prefectural Hospital Koseikan   (Japan)

Author keywords

EGFR TKI; Lung adenosquamous carcinoma; Plasma DNA; T790M

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; UFT;

ADENOSQUAMOUS CARCINOMA; ADULT; ARTICLE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LOBECTOMY; LUNG ALVEOLUS CELL CARCINOMA; LUNG CARCINOMA; METASTASIS; MICRODISSECTION; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; SQUAMOUS CELL CARCINOMA;

AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CARCINOMA, ADENOSQUAMOUS; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION;

EID: 84867796281     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.7428     Document Type: Article

References (14)

1. Shimizu J, Oda M, Hayashi Y, et al. A clinicopathologic study of resected cases of adenosquamous carcinoma of the lung. Chest 109: 989-994, 1996.
2. Nakagawa K, Yasumitu T, Fukuhara K, et al. Poor prognosis after lung resection for patients with adenosquamous carcinoma of the lung. Ann Thorac Surg 75: 1740-1744, 2003.
3. Gawrychowski J, Bruliński K, Malinowski E, et al. Prognosis and survival after radical resection of primary adenosquamous lung carcinoma. Eur J Cardiothorac Surg 27: 686-692, 2005.
4. Ichinose Y, Hara N, Takamori S, et al. DNA ploidy pattern of each carcinomatous component in adenosquamous lung carci-noma. Ann Thorac Surg 55: 593-596, 1993.
5. Kanazawa H, Ebina M, Ino-Oka N, et al. Transition from squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung. Am J Pathol 156: 1289-1298, 2000.
6. Toyooka S, Yatabe Y, Tokumo M, et al. Mutations of epidermal growth factor receptor and K-ras genes in adenosquamous carci-noma of the lung. Int J Cancer 118: 1588-1590, 2006.
7. Jia XL, Chen G. EGFR and KRAS mutations in Chinese patients with adenosquamous carcinoma of the lung. Lung Cancer 74: 396-400, 2011.
8. Kang SM, Kang HJ, Shin JH, et al. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 109: 581-587, 2007.
9. Shukuya T, Takahashi T, Kaira R, et al. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports. Cancer Sci 102: 1032-1037, 2011.
10. Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 11: 1167-1173, 2005.
11. Ichihara S, Toyooka S, Fujiwara Y, et al. The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer. Int J Cancer 120: 123912-123947, 2007.
12. Nakamura T, Sueoka-Aragane N, Iwanaga K, et al. A non-invasive system for monitoring resistance to EGFR tyrosine kinase inhibi-tors with plasma DNA. J Thorac Oncol 6: 1639-1648, 2011.
13. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemo-therapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 2380-2388, 2010.
14. Engelman JA, Jänne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895-2899, 2008.